Skip to content
10-Q

Quarterly Report

INHIBIKASE THERAPEUTICS, INC. IKT

0001193125-26-219641

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 132.03M sh
Shares Diluted Q1 2026 · Mar 31, 2026 172.31M sh
Shares Diluted Q1 2026 · Mar 31, 2025 89.54M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $13.4K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$12.06M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.1M
Stockholders Equity Q1 2026 · Mar 31, 2026 $167.62M
Stockholders Equity Q1 2026 · Dec 31, 2025 $172.9M
Stockholders Equity Q1 2026 · Mar 31, 2025 $85.73M
Stockholders Equity Q1 2026 · Dec 31, 2024 $94.87M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.71M
Current Liabilities Q1 2026 · Dec 31, 2025 $8.3M
Total Liabilities Q1 2026 · Mar 31, 2026 $5.71M
Total Liabilities Q1 2026 · Dec 31, 2025 $8.3M
Current Assets Q1 2026 · Mar 31, 2026 $172.18M
Current Assets Q1 2026 · Dec 31, 2025 $180.11M
Total Assets Q1 2026 · Mar 31, 2026 $173.33M
Total Assets Q1 2026 · Dec 31, 2025 $181.2M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.10
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.15
Eps Basic Q1 2026 · Mar 31, 2026 −$0.10
Eps Basic Q1 2026 · Mar 31, 2025 −$0.15
Sga Expense Q1 2026 · Mar 31, 2026 $7.38M
Sga Expense Q1 2026 · Mar 31, 2025 $5.25M
Rd Expense Q1 2026 · Mar 31, 2026 $10.84M
Rd Expense Q1 2026 · Mar 31, 2025 $10.51M
Net Income Q1 2026 · Mar 31, 2026 −$16.38M
Net Income Q1 2026 · Mar 31, 2025 −$13.68M
Operating Income Q1 2026 · Mar 31, 2026 −$17.84M
Operating Income Q1 2026 · Mar 31, 2025 −$14.6M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $0